China has granted approval to assess a third coronavirus vaccine candidate against Covid-19 in the second phase of clinical trials.
According to state-run Xinhua news agency, an inactivated vaccine created by Wuhan Institute of Biological Products under the China National Pharmaceutical Group, Sinopharm, and the Wuhan Institute of Virology (WIV) entered clinical trials.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
